Pioneering diagnostics

Timeline

  • 1963

    Establishment of BD Mérieux

    close
    1963
    photo-1963

    1963

    Establishment of BD Mérieux

  • 1967

    Launch by BD Mérieux of a fibrometer

    close
    1967
    photo-1967

    1967

    Launch by BD Mérieux of a fibrometer

    The fibrometer is added to the BD Mérieux catalog to test blood coagulation and is quickly adopted by a quarter (approx. 1,000) of France’s laboratories.

  • 1969

    The first toxoplasmosis detection kit and launch of miniaturized API® 20E strip

    close
    1969
    photo-1969

    1969

    The first toxoplasmosis detection kit and launch of miniaturized API® 20E strip

    • The first toxoplasmosis detection kit: diagnosis of toxoplasmosis by immunofluorescence.
    • Launch of miniaturized API® 20E strip by Api System*

    *Api System was acquired by bioMérieux in 1987.

  • 1972

    Production and sale of the first ready-to-use culture media in Petri plates.

    close
    1972
    photo-1972

    1972

    Production and sale of the first ready-to-use culture media in Petri plates.

  • 1974

    Alain Mérieux takes control of BD Mérieux, which becomes bioMérieux.

    close
    1974
    photo-1974

    1974

    Alain Mérieux takes control of BD Mérieux, which becomes bioMérieux.

  • 1974

    Launch of the Slidex® Meningitis kit.

    close
    1974
    photo-1974

    1974

    Launch of the Slidex® Meningitis kit.

    First test enabling the diagnosis of an infectious disease without prior culture, with results in 5 minutes compared to several days previously.

  • 1979

    ATB™ strip

    close
    1979
    photo-1979

    1979

    ATB™ strip

    First ATB™ Antibiotic Susceptibility test strip by Api System*

    *Api System was acquired by bioMérieux in 1987

  • 1985

    First HIV screening test: VIRONOSTIKA® HIV anti-HTLV-III by Organon Teknika*

    close
    1985
    photo-1985

    1985

    First HIV screening test: VIRONOSTIKA® HIV anti-HTLV-III by Organon Teknika*

    *Organon Teknika was acquired by bioMérieux in 2001

  • 1986

    Acquisition of Api Systems (La Balme, France).

    close
    1986
    photo-1986

    1986

    Acquisition of Api Systems (La Balme, France).

    A specialist in bacterial identification and antibiotic susceptibility testing systems.

    • ATB™ EXPRESSION™ et ATB™ Plus Expert for automated bacterial identification and antibiotic susceptibility testing
  • 1988

    Acquisition of Vitek Systems (United States)

    close
    1988
    photo-1988

    1988

    Acquisition of Vitek Systems (United States)

    A world leader in automated bacterial identification.

  • 1989

    Development of chromogenic media

    close
    1989
    photo-1989

    1989

    Development of chromogenic media

    Culture media that enables identification of microbial colonies by coloring them.

  • 1990

    Acquisition of the BOOM extraction and NASBA amplification technologies for molecular diagnostics.

    close
    1990
    photo-1990

    1990

    Acquisition of the BOOM extraction and NASBA amplification technologies for molecular diagnostics.

  • 1991

    Launch of the VIDAS® with 8 initial kits

    close
    1991
    photo-1991

    1991

    Launch of the VIDAS® with 8 initial kits

    Today VIDAS has 100 parameters.

  • 1992

    VIDAS® automated immunoassay platform adapted for industrial applications.

    close
    1992
    photo-1992

    1992

    VIDAS® automated immunoassay platform adapted for industrial applications.

  • 1995

    VIDAS® D-Dimer Exclusion™

    close
    1995
    photo-1995

    1995

    VIDAS® D-Dimer Exclusion™

    The first test used to rule out the diagnosis of deep vein thrombosis and pulmonary embolism to be certified by the FDA.

  • 1997

    Launches of BacT/ALERT® 3D and VITEK® 2

    close
    1997
    photo-1997

    1997

    Launches of BacT/ALERT® 3D and VITEK® 2

    • BacT/ALERT® 3D an advanced automated system for microbial detection in blood and sterile body fluid samples from Organon Teknika*
    • VITEK® 2 an automated identification and antibiotic susceptibility testing system for bacteria and fungi
    *Organon Teknika was acquired by bioMérieux in 2001.
  • 2001

    Acquisition of OrganonTeknika (Akzo Nobel, Netherlands).

    close
    2001
    photo-2001

    2001

    Acquisition of OrganonTeknika (Akzo Nobel, Netherlands).

    A pioneering company working in HIV screening and viral load measurement.

  • 2002

    NucliSENS EasyQ® and NucliSENS EasyQ® HIV-1

    close
    2002
    photo-2002

    2002

    NucliSENS EasyQ® and NucliSENS EasyQ® HIV-1

    NucliSENS EasyQ®, a molecular diagnostics platform for amplification and real-time detection.

    NucliSENS EasyQ® HIV-1, the first real-time test for measuring HIV-1 viral load.

  • 2004

    bioMérieux is listed on the stock exchange.

    close
    2004
    photo-2004

    2004

    bioMérieux is listed on the stock exchange.

  • 2004

    Launches of TEMPO® and VITEK® 2 Compact

    close
    2004
    photo-2004

    2004

    Launches of TEMPO® and VITEK® 2 Compact

    TEMPO®, for automated enumeration of quality indicators (bacteria, yeast and mold) for the agri-food industry.

    VITEK® 2 Compact, a system for identification and antibiotic susceptibility testing (AST).

  • 2006

    Acquisition of Bacterial Barcodes (USA)

    close
    2006
    photo-2006

    2006

    Acquisition of Bacterial Barcodes (USA)

  • 2007

    Acquisition of Biomedics (Spain) and of BTF (Australia)

    close
    2007
    photo-2007

    2007

    Acquisition of Biomedics (Spain) and of BTF (Australia)

    • Acquisition of Biomedics, manufacturer of culture media.
    • Acquisition of BTF, a specialist in industrial microbiology.
  • 2008

    Joint ventures and Acquisitions

    close
    2008
    photo-2008

    2008

    Joint ventures and Acquisitions

    • Acquisition of AB BIODISK (Sweden), a company internationally recognized for its antimicrobial resistance testing range and particular expertise in susceptibility testing of fastidious and unusual organisms.
    •  Acquisition of AviaraDx (USA), now bioTheranostics, a specialist in the molecular diagnosis of tumorous tissues.
    •  Acquisition of PML Microbiologicals (USA), a company devoted to the development and production of culture media.
    • Joint venture with Sysmex, the Japanese market leader in the field of in vitro diagnostics.
    •  Joint venture with Shanghai Kehua Bio-engineering (China) for the production of microplate immunoassays.

     
     

  • 2009

    Launches of PREVI® Isola and PREVI® Color Gram

    close
    2009
    photo-2009

    2009

    Launches of PREVI® Isola and PREVI® Color Gram

    PREVI® Isola for the automated inoculation of culture media.

    PREVI® Color Gram for automated Gram staining.

  • 2010

    Acquisition of Meikang Biotech and of Shanghai Zenka Biotechnology.

    close
    2010
    photo-2010

    2010

    Acquisition of Meikang Biotech and of Shanghai Zenka Biotechnology.

    Acquisition of Meikang Biotech (China), a manufacturer of rapid tests.
     
    Acquisition of Shanghai Zenka Biotechnology (China), a specialist in culture media.

  • 2010

    Launch of Myla® middleware

    close
    2010
    photo-2010

    2010

    Launch of Myla® middleware

    • Myla® middleware is a software solution for the optimization of laboratory workflow and clinical information management. It is a complement to FMLA® (Full Microbiology Lab Automation).
    • BacT/ALERT® 3D Dual-T, a microbial detection system used for sterility testing in the biopharmaceutical industry.

     

  • 2011

    Acquisition of AES Laboratoire (France).

    close
    2011
    photo-2011

    2011

    Acquisition of AES Laboratoire (France).

    An industrial microbiology company.

  • 2011

    Acquisition of ARGENE (France)

    close
    2011
    photo-2011

    2011

    Acquisition of ARGENE (France)

    A specialist in molecular biology.

  • 2011

    Launch of VITEK® MS

    close
    2011
    photo-2011

    2011

    Launch of VITEK® MS

    • Launch of VITEK® MS (used in association with the VITEK® 2 system) an automated mass spectrometry microbial identification system for clinical and industrial applications.
    • First bioNexia® rapid tests commercialized by bioMérieux.
    • Inauguration of the laboratory of the future at Marcy l’Étoile, France (over 1,000 visits from biologists and scientists in a year). Development of a similar unit in Saint Louis, Missouri (USA). The laboratories enable discussions to align bioMérieux’s future products and services with customer needs.
  • 2012

    Acquisition of RAS (India) and partnership with Quanterix

    close
    2012
    photo-2012

    2012

    Acquisition of RAS (India) and partnership with Quanterix

    • Acquisition of RAS, a specialist in molecular biology.
    • Partnership with Quanterix for the development of a new generation of ultrasensitive, multiplex immunoassays.
  • 2013

    FDA approval of novel molecular test THxID™-BRAF

    close
    2013
    photo-2013

    2013

    FDA approval of novel molecular test THxID™-BRAF

    A companion test for late stage metastatic melanoma tumor samples.

  • 2013

    VIDAS® 3

    close
    2013
    photo-2013

    2013

    VIDAS® 3

    The new generation of the VIDAS automated immunoassay platform.

  • 2014

    Acquisition of BioFire Diagnostics Inc.

    close
    2014
    photo-2014

    2014

    Acquisition of BioFire Diagnostics Inc.

    Acquisition of BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology.

  • 2014

    FDA clearance for the FilmArray® Gastrointestinal (GI) Panel

    close
    2014
    photo-2014

    2014

    FDA clearance for the FilmArray® Gastrointestinal (GI) Panel

    The 22-target FilmArray® GI Panel1 allows a syndromic approach2 to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test.

    A test panel is a predetermined group of medical tests used as an aid in the diagnosis and treatment of diseases.

    The syndromic approach is based on analyzing a syndrome (i.e. a set of symptoms) and, with a single reagent, identifying the disease-causing organisms responsible for this syndrome, whether they are viruses, bacteria or parasites.

     

  • 2014

    Launch of CE-marked VIRTUO™

    close
    2014
    photo-2014

    2014

    Launch of CE-marked VIRTUO™

    The new generation of BacT/ALERT®, VIRTUO™ is a uniquely innovative automated blood culture microbial detection system.

  • 1963
  • 1967
  • 1969
  • 1972
  • 1974
  • 1979
  • 1985
  • 1986
  • 1988
  • 1989
  • 1990
  • 1991
  • 1992
  • 1995
  • 1997
  • 2001
  • 2002
  • 2004
  • 2006
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014